HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gold Bond extensions

This article was originally published in The Tan Sheet

Executive Summary

TV ads for Antifungal Swabs, indicated for treatment of athlete's foot, will break in May with 30-second spots, dropping to 15-second after product introduction, Chattem says. Swabs contain tolnaftate 1%, employ "hands free" swab delivery system (1"The Tan Sheet" Sept. 30, 2002, p. 5). Similar ad schedule is planned for new First Aid Antiseptic Wipes, First Aid Antiseptic Quick Spray, which contain benzethonium chloride .13%, menthol 1%. Gold Bond extensions are reaching shelves now...

You may also be interested in...



Chattem Gold Bond Bolstered With Three New Products Shipping In 2003

Chattem is hoping three new Gold Bond line extensions - two in the first aid treatment category and one for athlete's foot - will drive double-digit growth in the brand in 2003

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128974

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel